A new form of #immunotherapy to treat #neuroblastoma using genetically engineered natural killer T cells shows promise in treating the disease. Initial results from the first 2 patients were presented today at #ASCGT by @bcmhouston's @HeczeyAndras. More: https://t.co/LCTFzVFWPi
Heard of CAR T-cells? What about CAR NKT-cells? Very early results from a new cell-based therapy being trialed in relapsed #neuroblastoma. It is always a good day when #childhoodcancer patients get trials of innovative therapies. By me in @ForbesHealth https://t.co/V6vpbo5lPT
Cell Medica collaborators, Baylor College of Medicine and Texas Children’s Hospital, present preclinical data for an off-the-shelf CAR-NKT therapy platform https://t.co/nwRLwRrlqu
Cell Medica announces the treatment of the first patient world-wide to receive CMD-501, an autologous CAR-NKT therapy targeting pediatric neuroblastoma. #celltherapy#carnkt https://t.co/kn5Y3SVxI1
Further development of @CellMedica's WT1 gene-modified T cell therapy will take place at the Cell and Gene Therapy Catapult manufacturing centre #WT1#genetherapy#manufacturing - https://t.co/JDJMNojDHC
We are the first floor exhibition area where @GregClarkMP and @SamGyimah are meeting some of our collaborators and supply chain partners who are part of the manufacturing centre story @Adaptimmune@CellMedica#Autolus@thermofisher
It is great to be able to attend the opening of the @CGTCatapult manufacturing centre in Stevenage today. Read the press release for more information - https://t.co/Jm35zN2h3H
We are excited to welcome members of global industry and academia to the official opening of our large-scale GMP manufacturing centre at @SteBioCat next week #innovation#celltherapy#genetherapy - https://t.co/I7XIEuFpG7